{"id":"W3205063602","doi":"10.1016/s1470-2045(21)00494-0","title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Cancer Institute; Medical Research Council; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Azacitidine; Medicine; IDH2; Internal medicine; Myeloid leukaemia; Population; Clinical endpoint; Myeloid leukemia; Oncology; Myeloid; Clinical trial; Surgery; IDH1; Mutant; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009305975,0.001713826,0.002418461,0.0003038015,0.0002255849,0.001139227,0.0007466492,0.001237175,0.005603321],"category_scores_gemma":[0.0009645696,0.0004794878,0.001506207,0.0003057952,0.0007347413,0.001003442,0.0003829204,0.003048736,0.0009485829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008664911,"about_ca_system_score_gemma":0.0006633442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001032245,"about_ca_topic_score_gemma":0.003714138,"domain_scores_codex":[0.9997252,0.0001284006,0.00001290491,0.00005993887,0.00001944261,0.00005420161],"domain_scores_gemma":[0.9996102,0.00009330346,0.0000750645,0.00002504964,0.00001714293,0.0001792304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9511433,0.004189512,0.001081076,0.0007230324,0.001491838,0.00008276956,0.00009697834,0.001008396,0.004770638,0.0002678117,0.002024811,0.03311982],"study_design_scores_gemma":[0.9309239,0.06240205,0.00310914,0.00004431646,0.0005961697,0.00009521887,0.00004883912,0.0006672574,0.0004518596,0.0003170269,0.001326501,0.00001757347],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873036,0.006350046,0.0003375426,0.001019233,0.0005957478,0.0008169428,0.000995614,0.0001115135,0.002469724],"genre_scores_gemma":[0.9865367,0.003838395,0.0008620211,0.001230436,0.0004044745,0.0008649774,0.001659594,0.0000249998,0.00457846],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005603321,"threshold_uncertainty_score":0.01874495,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04659093949864618,"score_gpt":0.3497902769540706,"score_spread":0.3031993374554244,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}